Scientific Reports · 2021 · 23 citations · 30 references
MedicineCell BiologyOncologyMetastasisMolecular OncologyNeoplasiaCancer EpigeneticsCancer ProgressionEpigenetic Alterations In CancerEpigenetic Regulation In CancerNeuroendocrine Tumor TherapyNeuroendocrine TumorsApoptosis TargetingEpigenetic DeregulationGastrointestinal Neuroendocrine TumorsHistone Methyltransferase InhibitionNeoplastic ProgressionNeuroendocrine Tumor PharmacologyNeuroendocrine Tumor PharmacotherapySmall Intestinal Neuroendocrine Tumors
Small intestinal neuroendocrine tumors (SI-NETs) are slow-growing tumors that seem genetically quite stable without highly recurrent mutations, but are epigenetically dysregulated. In contrast to the undetectable expression of the enhancer of zeste homolog 2 (EZH2) histone methyltransferase in the enterochromaffin cells of the small intestine, we found high and differential expression of EZH2 in primary SI-NETs and corresponding metastases. Silencing EZH2 in the SI-NET cell line CNDT2.5 reduced cell proliferation and induced apoptosis. Furthermore, EZH2 knockout inhibited tumor progression in a CNDT2.5 SI-NET xenograft mouse model, and treatment of SI-NET cell lines CNDT2.5 and GOT1 with the EZH2-specific inhibitor CPI-1205 decreased cell viability and promoted apoptosis. Moreover, CPI-1205 treatment reduced migration capacity of CNDT2.5 cells. The EZH2 inhibitor GSK126 also repressed proliferation of CNDT2.5 cells. Recently, metformin has received wide attention as a therapeutic option in diverse cancers. In CNDT2.5 and GOT1 cells, metformin suppressed EZH2 expression, and inhibited cell proliferation. Exposure of GOT1 three-dimensional cell spheroids to CPI-1205 or metformin arrested cell proliferation and decreased spheroid size. These novel findings support a possible role of EZH2 as a candidate oncogene in SI-NETs, and suggest that CPI-1205 and metformin should be further evaluated as therapeutic options for patients with SI-NETs.
30
The polycomb group protein EZH2 is involved in progression of prostate cancer
Sooryanarayana Varambally, Saravana M. Dhanasekaran, Ming Zhou et al. · Nature · 2002 · 2.7K citations · Full text
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe, Heidi M. Ott, Gopinath Ganji et al. · Nature · 2012 · 1.8K citations
Ingeborg Bachmann, Ole J. Halvorsen, Karin Collett et al. · Journal of Clinical Oncology · 2005 · 844 citations
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors
Joshua M. Francis, Adam Kieżun, Alex H. Ramos et al. · Nature Genetics · 2013 · 373 citations · Full text